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RISK FACTORS ASSOCIATED WITH INCREASED GRADES III-IV ACUTE
GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (HCT)
Sorror, M.1, Gooley, T.1, Nash, R.1,2, Petersdorf, E.1,2, Martin, P.1,2,
Deeg, H.J.1,2, Baron, F.1, Davis, C.1, Sanders, J.1,2,
Flowers, M.E.D.1,2, Carpenter, P.1,2, Witherspoon, R.1,2,
Appelbaum, F.1,2, Storb, R.1,2 1. Fred Hutchinson Cancer Research
Center, Seattle, WA; 2. University of Washington, Seattle, WA.
Grades III-IV acute GVHD are associated with worse survival
compared to grades 0-II GVHD (Leukemia. 2004;18:1013). We in-
vestigated risk factors for development of grades III-IV GVHD
among 958 patients (pts) who received a myeloablative HCT between
1993 and 2002. Donor grafts were from HLA-identical siblings (n 
709) or unrelated donors who were matched for 10 of 10 HLA alleles
by high-resolution typing (n 249). GVHD prophylaxis consisted of
methotrexate (MTX) and cyclosporine (CSP). Conditioning included
120 mg/kg cyclophosphamide, combined with busulfan 16 mg/kg
(n  436) or 8-15 Gy fractionated total body irradiation (n  410).
Underlying diagnoses were classiﬁed as low-risk (acute leukemia-ﬁrst
remission, chronic myeloid leukemia-chronic phase, myelodysplasia-
refractory anemia, and non-malignant hematological disease) or high-
risk (other diagnoses). Pretransplant comorbidities were scored using
HCT-comorbidity index (HCT-CI, Blood. 2005;106:2912); where
35% of pts had scores 2-4, and 5% scores 5. After HCT, 15% of
related and 27% of unrelated pts developed grades III-IV acute
GVHD, respectively. Incidences of grades III-IV GVHD were 16%,
23%, and 45% for pts with HCT-CI scores of 0-3 vs 4 vs 5, and
15% vs 22% for pts with low vs high-risk diseases. Multivariable Cox
regression models were used to analyze possible risk factors for grades
III-IV GVHD. HCT-CI scores of5 (P .0001), high-risk diseases
(P .008), and80% CSP dosing (P.008) were associated with an
increased hazard of grades III-IV GVHD (Table 1). The magnitude
of these effects was similar between related and unrelated pts. MTX
dose 80% was a risk factor only among related pts (P  .02), and
unrelated grafts were a signiﬁcant risk factor among pts given 	80%
MTX dosing (P  .0001). Only 19 unrelated and 66 related pts
received 80% MTX dosing. The odds of receiving reduced dose of
CSP among pts 	20 years was 5.04 (95% CI, 2.99-8.5, P  .0001)
times that among pts 20 (incidences of reductions in CSP dosing
were 34%, 69%, 73%, and 76% among pts aged 20, 20-40, 40-50,
and 	50 years), although age was not statistically signiﬁcantly asso-
ciated with severe GVHD. The majority of pts 20 years had
HCT-CI scores of 0 (68%) vs 46% of older pts (P  .0002). These
results suggest that pts with high comorbidity scores or advanced
disease should be stratiﬁed in future clinical trials for GVHD pro-
phylaxis. The age related reductions of CSP dosing were likely due to
increasing comorbidities with increasing age (Table 1).
Table 1. Grades III–IV Acute GVHD
Risk Factors
Hazard
Ratio 95% CI
P
Value
HCT-CI scores 0–4 1 — —
>5 3.05 1.34–5.05 <.0001
Disease risk Low 1 — —
High 1.55 1.12–2.14 .008
CSP use* >120% 0.76 0.49–1.18 .23
80–120% 1 — —
<80% 1.95 1.19–3.18 .008
MTX use* (among
related recipients)
>80% 1 — —
<80% 1.96 1.12–3.57 .02
Donor (among pts
given >80% MTX
dosing)
Related
recipients
1 — —
Unrelated
recipients
2.60 1.68–3.31 <.0001
*Modeled as a time-dependent covariate, denotes percentage of
prescribed amount that was received. For CSP, % received is based
on prescribed amounts per week through 7 weeks post-transplant,
and for MTX, % received is based on amounts per day on days 1,
3, 6, and 11 (N Engl J Med 1986;314:729). Type of donor and %
MTX dosing show a statistically signiﬁcant interaction (P  .03).
Factors included in the analysis are: Patient age, donor age, type of
donor, TBI versus chemotherapy-based conditioning, doses of
TBI, disease risk, year of HCT, marrow vs peripheral blood mono-
nuclear cells, source of stem cells, and 80% reduction of doses of
CSP or methotrexate.
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ISOLATION AND CHARACTERIZATION OF HUMAN CD4CD25 T REG-
ULATORY CELLS FOR EARLY PHASE CLINICAL TRIALS IN HEMATOPOI-
ETIC CELL TRANSPLANTATION
Hou, J.-Z.1,2, Baker, J.1, Sheehan, K.1, Negrin, R.S.1 1. Division of
Bone Marrow Transplantation, Department of Medicine, Stanford Uni-
versity School of Medicine, Palo Alto, CA; 2. Division of Hematology,
Department of Medicine, Stanford University School of Medicine, Palo
Alto, CA.
Naturally occurring CD4CD25 T regulatory cells (Tregs)
are a subpopulation of CD4 T cells vital to homeostasis and
maintenance of tolerance. Tregs suppress the proliferation and
expansion of conventional CD25CD4 and CD8 T cells
through direct cell-cell contact. Our laboratory has shown that
co-transplantation of Tregs with conventional CD4 and CD8
T cells suppressed acute graft versus host diseases (GVHD) with-
out abrogating graft versus tumor (GVT) effects in murine bone
marrow transplant models. Translating this novel strategy holds
great promise not only in clinical hematopoietic cell transplanta-
tion, but also in adoptive cellular therapy beyond hematopoietic
cell transplantation. Large scale isolation of sufﬁcient human
Tregs for therapeutic application remains challenging. Tregs com-
prise 2-10% of CD4 T cells. In contrast to rodent Tregs, human
CD25 is also expressed at lower level by activated conventional T
cells or B cells. Here, we explore the isolation and characterization
of human CD4CD25 Tregs from peripheral blood mononu-
clear cells (PBMC) of healthy blood donors and from CD34 cell
depleted fraction of allogenic donors. CD25 cells were isolated
by three different approaches: 1) CD4 enrichment followed by
CD25 selection, 2) CD19 depletion followed by CD25 selec-
tion, 3) CD25 selection without prior enrichment or depletion.
The purities of isolated CD4CD25 cells were 95%, 93%, and
93% respectively. The isolated CD25 cells were then sorted
into CD4CD25High and CD4CD25Low, ﬁxed and stained
for intracellular expression of FoxP3. More than 95% of
CD4CD25bright cells expressed FoxP3. In contrast, only 30-
40% of CD4CD25dim cells expressed FoxP3. No FoxP3 ex-
pression was detected in CD4CD25 cells. Using multi-color
FACS, we observed that human FoxP3CD4CD25High cells
express high levels of CD27 (98%), CD28 (100%), and CD30
(50%) and low levels (10%) of CTLA-4, GITR, 4-1BB, PD-1
and ICOS on the cell surface. However, CTLA-4, GITR, PD-1
and ICOS were expressed intracellularly in more than 50% of
FoxP3CD4CD25High cells. OX40, TRAIL, ICOS ligand
and FasL were not detected on the cell surface or in the cyto-
plasm of FoxP3CD4CD25bright cells. In summary, highly
puriﬁed CD4CD25 Treg cells can be isolated by magnetic
beads and cell sorting. Importantly, the majority of the cells
express FoxP3. Utilizing this technique, the clinical application
of Tregs appears feasible.
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IN VITRO CULTURED ALLOGENEIC CYTOTOXIC T CELLS MEDIATE
HEMATOPOIETIC GVHD WITHOUT GUT GVHD DESPITE EXPRESSION
OF FUNCTIONAL LPAM (	47 INTEGRIN)
Kalpatthi, R., Nicol, K., Hendey, L., Boyer, M. Children’s Hospital,
Columbus, OH.
We and others have shown that in vitro cultured CD8 cyto-
toxic T cells (CTL) have attenuated GVHD. It has been shown
that expression of LPAM on CD8 T cells is important for gut
homing speciﬁcity in GVHD. Recently, retinoic acid (RA) has
been shown to upregulate LPAM expression on naive T cells.
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